Physician profile
Jahnavi Koppala
NPI 1225292998
$2,373.59
in general payments reported to CMS, 2019-2025
19 companies · $556 in 2025
The $556 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $124 · 2021: $162 · 2022: $79.17 · 2023: $172 · 2024: $348 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.54 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $800.00 | 2019 | |
| Abbvie INC. | $474.89 | 2019-2025 | |
| Janssen Biotech, INC. | $347.86 | 2020-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $101.77 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.32 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $84.55 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $67.76 | 2020-2022 | |
| Celgene Corporation | $58.70 | 2023-2024 | Zeposia |
| Abiomed | $58.35 | 2021 | |
| Qol Medical, LLC | $43.27 | 2020 | |
| Ironwood Pharmaceuticals, INC | $41.86 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $33.16 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $31.07 | 2025 | |
| Conmed Corporation | $30.38 | 2023 | Conmed Dilation, Conmed Generators |
| Janssen Scientific Affairs, LLC | $25.65 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $22.29 | 2019 | |
| Lilly USA, LLC | $22.03 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $14.60 | 2022 | |
| Aimmune Therapeutics, INC. | $14.08 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jahnavi Koppala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.